Unknown

Dataset Information

0

Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.


ABSTRACT: Infusion of allogeneic NK cells is a potential immunotherapy for both hematopoietic malignancies and solid tumors. Interactions between killer immunoglobulin-like receptors (KIR) on human NK cells and KIR-ligands on tumor cells influence the magnitude of NK function. To obtain sufficient numbers of activated NK cells for infusion, one potent method uses cells from the K562 human erythroleukemia line that have been transfected to express activating 41BB ligand (41BBL) and membrane-bound interleukin 15 (mbIL15). The functional importance of KIRs on ex vivo expanded NK cells has not been studied in detail. We found that after a 12-day co-culture with K562-mbIL15-41BBL cells, expanded NK cells maintained inhibition specificity and prior in vivo licensing status determined by KIR/KIR-ligand interactions. Addition of an anti-CD20 antibody (rituximab) induced NK-mediated antibody-dependent cellular cytotoxicity and augmented killing of CD20+ target cells. However, partial inhibition induced by KIR/KIR-ligand interactions persisted. Finally, we found that extended co-cultures of NK cells with stimulatory cells transduced to express various KIR-ligands modified both the inhibitory and activating KIR repertoires of the expanded NK cell product. These studies demonstrate that the licensing interactions known to occur during NK ontogeny also influence NK cell function following NK expansion ex vivo with HLA-null stimulatory cells.

SUBMITTER: Wang W 

PROVIDER: S-EPMC5477646 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Wang Wei W   Erbe Amy K AK   Alderson Kory A KA   Phillips Emily E   Gallenberger Mikayla M   Gan Jacek J   Campana Dario D   Hank Jacquelyn A JA   Sondel Paul M PM  

Cancer immunology, immunotherapy : CII 20160708 9


Infusion of allogeneic NK cells is a potential immunotherapy for both hematopoietic malignancies and solid tumors. Interactions between killer immunoglobulin-like receptors (KIR) on human NK cells and KIR-ligands on tumor cells influence the magnitude of NK function. To obtain sufficient numbers of activated NK cells for infusion, one potent method uses cells from the K562 human erythroleukemia line that have been transfected to express activating 41BB ligand (41BBL) and membrane-bound interleuk  ...[more]

Similar Datasets

| S-EPMC5123674 | biostudies-literature
| S-EPMC9968158 | biostudies-literature
| S-EPMC7817297 | biostudies-literature
| S-EPMC5609756 | biostudies-literature
| S-EPMC3438391 | biostudies-literature
| S-EPMC6886768 | biostudies-literature
| S-EPMC3824577 | biostudies-literature
| S-EPMC540275 | biostudies-literature
| S-EPMC3081247 | biostudies-literature
2015-04-23 | E-GEOD-62654 | biostudies-arrayexpress